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Abstracts / Urological Science 27 (2016) S36eS52S50survival (PFS) deﬁned as no biochemical relapse (two consecutive rises in
prostate-speciﬁc antigen [PSA] with a velocity>0.4 ng/ml per year or PSA
>1.5 ng/ml) and no additional treatment. Adverse events in terms of
genitourinary and gastrointestinal toxicity were reported.
Results: Themean follow-up of the 121 patients was 32.7months and total
11 patients underwent salvage radiotherapy. Six patients received SRT and
hormone therapy. Five patients received SRT alone. 6-month progression-
free survival was observed in total 6 patients receiving SRT and hormone
therapy achieved. However, biochemical relapse was documented in two
patients, 9.47 and 12.20 months after salvage treatment completed,
respectively. Among 5 patients receiving SRT alone, two patients
encountered treatment failure. There is 1 patient who had histologically
proven local relapse. 6-month progression-free survival was observed in
the other 2 patients. Salvage radiotherapy was discontinued on 1 patient,
who developed grade 4 ileus after 2400 cGy of radiation. There was also 2
patients getting grade 3 gastrointestinal toxicity, bloody stool and anal
ulcer with bleeding, respectively. Otherwise, gastrointestinal toxicity was
low. All genitourinary toxicity are grade 1e2. Three patients had no
genitourinary symptom.
Conclusion: In this preliminary study, combined radiotherapy and hor-
mone therapy seemed provided satisfactory oncologic control after for
salvage treatment after primary HIFU failure. Though genitourinary and
gastrointestinal toxicity were usually low, Grade 3e4 toxicity was still
noted. These results warrant further and longer investigation.
MP6-2.
PSA FLARE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
PATIENTS TREATED WITH ABIRATERONE OR DOCETAXEL
Hui-Ying Liu, Yuan-Chi Shen, Cheng-Jen Yu, Po-Hui Chiang. Division of
Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
College of Medicine, Taiwan
Purpose: The aim of this study was to assess PSA ﬂare up phenomenon in
the treatment of metastatic castration-resistant prostate cancer (mCRPC)
patients with abiraterone or docetaxel and to correlate with clinical
outcome.
Materials and Methods: We retrospectively evaluated 92 patients with
metastatic castrate-resistant prostate cancer (CRPC) either treated with
abiraterone or docetaxel at our institution. Baseline serum PSA levels were
checked before treatment and followed bymonitoring every 4weeks in the
group of abiraterone and every cycle in the groupof docetaxel. The PSAﬂare
phenomenonwas evaluated. Clinical outcomes were evaluated to compare
survival between groups of patients according to variations of PSA level.
Results: Of 92 patients, 73 patients received docetaxel therapy and 19
patients treated with abiraterone. They were classiﬁed into four groups:
stabilization (PSA decline <50%), PSA progression, primary responder (PSA
decline S 50%), and ﬂare-up phenomenon. Six patients (8.2%) got doce-
taxel therapy and two patients (10.5%) got abiraterone therapy were
identiﬁed with PSA ﬂare phenomenon. We compared the overall survival
between group of PSA decline> 50% with the ﬂare-up group. There was no
statistical difference in survival between two groups.
Conclusion: There is a considerable portion of mCRPC patients experience
PSA ﬂare under either abiraterone or docetaxel therapy. There was no
statistical difference in survival between PSA responder and PSA ﬂare-up
phenomenon group. Patients should be informed of this effect to avoid
early, and thereby inadequate, discontinuation of treatment.
MP6-3.
SYSTEMIC REVIEW OF MALIGNANCY AFTER ILEOCYSTOPLASTY
Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions
of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,
Taiwan
Purpose: The incidence of post-ileocystoplasty malignancy is low and
most published reports were case reports and only few single-cancer
retrospective cohort study presented. Therefore, we systemically reviewed
the published reports to pool the results for analysis to more clearly
illustrate the characteristics and prognosis of malignancy associated with
ileocystoplasty.Materials and Methods: We did a systemic search of the PubMED® and
CiNii for all cases with the following keywords: cystoplasty, enter-
ocystoplasy, ileocystoplasty, ileum, urinary diversion, and malignancy or
bladder cancer. The additional records on this topic were identiﬁed from
references cited in the selected articles and previous review articles on this
topic. Two of the authors (CWL and SJC) independently did the literature
search and data extraction. The parameters retrieved from the reports
included baseline patient characteristics, latency period, indications for
surgery, presenting symptoms and signs, histological type, locus of tumor,
follow-up period and survival which were analyzed with commercial
software (Medcalc®, version 9.3, USA).
Results: There were 41 articles selected and analyzed prudently with 56
cases included in the review. The reported incidence ranged from 0.9% to
5.5% in patients underwent ileocystoplasty. The average age was
53.0 ± 11.8 years old. Most malignancy occurred 15 years after ileocysto-
plasty (47/56, 83.9%) and the most commonly presenting symptoms were
gross hematuria (60.0%). The locations of malignancy were mainly located
at the ileobladder junction. Adenocarcinoma is most commonly observed
histology among all cases (39/56) while urothelial carcinoma predomi-
nated in cases with neurogenic bladder (5/10). 17 of 45 patients (37.8%)
presented with advanced disease and poor prognosis (median survival
time was 6.0 months).
Conclusion: The systemic review revealed low incidence of post-ileocys-
toplasty malignancy with majorly poor prognosis. Yearly cystoscopy sur-
veillance may not be indicated in case within 15 years post-operatively
except symptomatic patients.
MP6-4.
A PRELIMINARY REPORT: THE APPLICATION OF HO-YAG LASER IN
TURBT WITH ENBLOC METHOD
Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions
of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,
Taiwan
Purpose: The traditional TURBT surgery still have several drawbacks
include fragmentation, cauterization effect and easily disorientation. In
here, we reviewed our patients receiving laser en bloc TURBT to compared
the traditional TURBT with the feasibility, oncology outcome and
complication rate.
Materials and Methods: We reviews patients newly diagnosed and
received TURBT surgery in our hospital from 2011 to 2014. Patients who
were loss of following up/ under unresectable status were all excluded. The
age, body weight, height and sex were all recorded. The number, grade and
stage of tumor were all recorded. Also, the complication during the
operation were also reviewed based on medical record.
Results: From2011 to 2014, therewere 10 patients received laser TURBTand
52 patients received traditional TURBTsurgery. The detrusormuscle harvest
rate was 91.6% in Laser TURBT group and 77.4% in traditional TURBT group
(p¼0.44). Themean following timewas 25.5months (Median 23.1months).
The total recurrence ratewas 11.9% (2/9) in Laser TURBTgroupand22.4% (13/
58) in cTa/ cT1/ cT2 group. In comparison the recurrence rate inT1/ Ta group,
the detrusormuscle (+) group has lower recurrence rate in both laser TURBT
group (25.0%) and traditional TURBTgroup (24.2%) than the detrusormuscle
() group (40%). All the procedures have no complication recorded.
Conclusion: The application of laser with En-bloc method in TURBT is a
good alternative which could increase the diagnosis accuracy and lower
the recurrence rate.
MP6-5.
COMPARISONS OF FUNCTIONAL OUTCOMES AND QUALITY OF LIFE
AFTER NEOBLADDER RECONSTRUCTION: PROSTATE-SPARING
CYSTECTOMY VERSUS RADICAL CYSTOPROSTATECTOMY
Chiang Po Hui, Chen Po Yen. Kaohsiung Chang Gung Medical Center,
Department of Urology, Taiwan
Purpose: To compare functional outcomes on erectile function, conti-
nence, voiding functions, and life quality among bladder patients under-
went neobladder reconstruction after prostate-sparing cystectomy (PSC)
and conventional radical cystoprostatectomy (CRC).
Abstracts / Urological Science 27 (2016) S36eS52 S51Materials and Methods: We recorded I-PSS, IIEF, European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire-Core
30-item questionnaire (EORTC-QLQ-C30), catheterizations, and measure
urinary ﬂow and residual urine to evaluate the functional outcomes and in
the baseline, post-operation 1 and 2 years among the patient with bladder
cancer which received PRC and CRC.
Results: During 2007 to 2013, we identiﬁed 23 males with bladder cancer
who underwent neobladder reconstruction, 13 patients with PRC and the
other 10 patients with CRC. We found that there were better sexuality
preservation, continence rate and better global health status, functional
scales, and symptom scales in the PRC group.
Conclusion: For patients with bladder cancer underwent neobladder
reconstruction, prostate-sparing cystectomy provides better sexuality
preservation, continence rate, and quality of life.
MP6-6.
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR AND TRANSARTERIAL
EMBOLIZATION OF TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED
RENAL ANGIOMYOLIPOMA: A CASE SERIES
Wei-Chung Hsiao 1, Jeng-Dau Tsai 2, Yu-Lin Kao 1,3, Shao-Chuan Wang 1,
Wen-Jung Chen 1, Tzuo-Yi Hsieh 1, Sung-Lang Chen 1,3. 1Department of
Urology, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC;
2Department of Pediatrics, Chung Shan Medical University Hospital,
Taichung, Taiwan, ROC; 3 School of Medicine, Chung Shan Medical
University, Taichung, Taiwan, ROC
Purpose: Renal angiomyolipomas (AML) are benign tumors composed of
blood vessels, smooth muscle cells and fat cells. AML-related chronic
kidney disease and tumor bleeding are the main cause of mortality. AML
are highly associatedwith Tuberous Sclerosis Complex (TSC) andmostly be
treated by mammalian target of rapamycin inhibitor (mTORi) therapy or
transarterial embolization (TAE).
Materials and Methods: Here we present our cases of TSC-associated
renal AMLs treated with monotherapy or combined treatment of mTORi
and TAE. A total of 19 patients (4 males and 15 females) were included.
There were 10 patients treated by mTORi only and 9 by combined therapy
with mTORi and TAE.
Results: Themean age of the patientswas 34.5 (14e72) years. Themaximal
diameters of renal AMLs were from 1.5 to 20.9 (9.3±6.1) cm. During a mean
follow-up duration of 43 (6e81) months, the size of AMLs decreased
15e33% in 8 patients receiving combination therapy. Two patients under-
gone monotherapy experienced 30-50% increase of tumor diameter. The
tumor size of other patients showed no statistically signiﬁcant change.
Conclusion: TSC-associated AMLs are quite common in this hereditary,
complex syndrome. They are usually multiple and bilateral. The lesion
usually progress over time and complicated with ﬂank pain, hemorrhage,
and even renal deterioration. TSC-associated AMLs can be treated by
medication or minimally invasive therapy. Our result discovered although
the tumor size may not shrink, TAE still play an important role in man-
agement of tumor bleeding with acceptable complications. In our study,
combination therapy showed better control of tumor size than mono-
therapy alone in TSC-associated AMLs.
MP6-7.
CHARACTERISTICS OF MEN YOUNGER THAN 55 YEAR-OLD RECEIVING
TRANSRECTAL ULTRASOUND PROSTATE NEEDLE BIOPSY (TRUS
BIOPSY)dTHE EXPERIENCE OF THE COMMUNITY HOSPITAL
Po-Jen Huang 1, Yi-Chun Chiu 1,2,3. 1Division of Urology, Department of
Surgery, Taipei City Hospital, Zhong-xiao Branch, Taiwan; 2Division of
Urology, Department of Surgery, Taipei City Hospital, Ren-Ai branch,
Taiwan; 3Department of Urology, School of Medicine, National Yang-Ming
University, Taipei, Taiwan
Purpose: Early detection of prostate guideline from American Urological
Association (AUA) in 2013 does not recommend routine prostatic speciﬁc
antigen (PSA) screening in men younger than 55 year-old at average risk.
The purpose of this study is to investigate the characteristics of TRUS bi-
opsy for patients younger than age of 55, in a hope to assess the beneﬁt of
TRUS biopsy and the occurrence of prostate cancer in this population.Materials andMethods: Based on retrospective medical records, 812male
patients who received TRUS biopsy during December 2007 to December
2014 at Zhongxiao Branch of Taipei City Hospital were included. Of them,
57 men (7%) were younger than ﬁfty ﬁve year-old. We compare the age,
pre-biopsy, PSA, prostate size, and adenoma size between prostate cancer
group and benign prostatic hyperplasia group.
Results: In these 57 men, 6 of them (10.5%) had prostate cancer (group A),
and 51 men had benign prostatic hyperplasia (group B). The average age of
the group A and B was 51.0 ± 3.7 and 50.8 ± 3.1 year-old (P¼0.23). The
mean PSA of group A and B was 15.3 ± 12.3 and 7.2 ± 4.5 ng/ml (P<0.05).
The mean prostate size of group A and B was 23.3 ± 6.1 and 33.6 ± 14.8 ml
(P¼0.04). The mean adenoma size of group A and B was 8.7 ± 3.0 and
10.3 ± 5.5 ml (P¼0.12).
Conclusion: Among selected male patients younger than age of 55, TRUS
biopsy was with a positive detection rate of 10%, and prostate cancer may
be detected in patients with higher level PSA and smaller prostate size.
MP6-8.
THE CLINICAL EFFICACY OF NEOADJUVANT CHEMOTHERAPY ON
UROTHELIAL CARCINOMA OF THE BLADDER: A RETROSPECTIVE
ANALYSIS FROM A SINGLE-CENTER IN TAIWAN
Ming Cheng Luo, Ying-Hsu Chang, Cheng-Keng Chuang, See-Tong Pang,
Po-Hung Lin, Chung-Yi Liu. Divisions of Urology, Department of Surgery,
Chang Gung Memorial Hospital, Linkou, Taiwan
Purpose: Current evidence supports neoadjuvant chemotherapy in the
treatment of advanced bladder cancer. We intend to compare clinical
outcomes in patients treated for MIBC with neoadjuvant chemotherapy at
our institution.
Materials and Methods: We retrospectively reviewed total 26 patients
received neoadjuvant chemotherapy from Jan. 2012 to Feb. 2016 in Linkou
Chang Gung Memorial Hospital. Twenty of 26 patients completed neo-
adjuvant chemotherapy, followed by radical cystectomy and urothelial
bladder carcinoma was pathologically proven.
Results: The median time from diagnosis to operation is 3.45 months
(1.38e3.65). Two of 20 (10%) patients have pathological complete
response, Ten of 20 (50%) patients have partial response and Two of 20
(10%) have stable disease. The mean time of disease free survival (time
from surgery to recurrence) is 22.47 months. The mean time of overall
survival (time from surgery to recurrence) is 25.72 months
Conclusion: Our data revealed that neoadjuvant chemotherapy in bladder
cancer have 10% complete response rate and signiﬁcant downstaging of
urothelial carcinoma with 60%. However, more such studies with larger
sample sizes and longer follow-ups are needed and we intend to stan-
dardize the regimen of neoadjuvant chemotherapy to evaluate the efﬁcacy
much precise.
MP6-9.
CAPSAICIN INDUCES APOPTOSIS AND CELL CYCLE ARREST IN BLADDER
CANCER TSGH-8301 CELLS
Ming-Hung Lin 1,2, Pin-Ju Chueh 2. 1Divisions of Urology, Department of
Surgery, China Medical University-An Nan Hospital, Taiwan, ROC;
2 Institute of Biomedical Sciences, National Chung Hsing University,
Taichung, Taiwan, ROC
Purpose: To explore the involvement of tNOX in capsaicin-exposed
bladder cancer cells, particularly, apoptotic signaling pathways.
Materials and Methods: In this study, we investigated the effect of
capsaicin on human bladder cancer cell lines TSGH 8301, and tried to
clarify the relevant inhibition of cancer of the mechanism. The cell
numbers were detected by ﬂowcytometry. ROS and MMP assay were used
to check cell survival stress and mitochondrial permeability. Western blot
analysis was used to study protein expression proﬁles of apoptosis and cell
cycle arrest.
Results: We found that the TSGH 8301 cell growth was inhibited by
capsaicin with dose dependent and there was signiﬁcant cell apoptosis.
The cell cycle arrested at G1 / S phase. The ROS assay and MMP assay
signiﬁcantly revealed increased cell survival stress and mitochondrial
permeability. By the Western blot analysis, we found that in 100uM and
